Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody

Eur J Cancer. 2019 Jan:106:193-195. doi: 10.1016/j.ejca.2018.10.025. Epub 2018 Dec 5.

Authors

T Shirai¹, Y Kiniwa², R Sato¹, T Sano¹, K Nakamura¹, Y Mikoshiba¹, N Ohashi³, Y Sekijima³, R Okuyama¹

Affiliations

¹ Department of Dermatology, Shinshu University School of Medicine, Japan.
² Department of Dermatology, Shinshu University School of Medicine, Japan. Electronic address: [email protected].
³ Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan.

PMID: 30528803
DOI: 10.1016/j.ejca.2018.10.025

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Autoantibodies / blood*
Glucocorticoids / administration & dosage
Humans
Male
Melanoma / drug therapy*
Melanoma / immunology
Melanoma / secondary
Muscle, Striated / immunology*
Myasthenia Gravis / chemically induced*
Myasthenia Gravis / diagnosis
Myasthenia Gravis / immunology
Myasthenia Gravis / therapy
Myocarditis / chemically induced*
Myocarditis / diagnosis
Myocarditis / immunology
Myocarditis / therapy
Myositis / chemically induced*
Myositis / diagnosis
Myositis / immunology
Myositis / therapy
Plasma Exchange
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Pulse Therapy, Drug
Receptors, Cholinergic / immunology*
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
Skin Neoplasms / pathology
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Autoantibodies
Glucocorticoids
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Receptors, Cholinergic
pembrolizumab